Search Results - "Bárez, A."

Immunophenotypic analysis of Waldenstrom's macroglobulinemia by San Miguel, J.F., Vidriales, M.B., Ocio, E., Mateo, G., Sánchez-Guijo, F., Sánchez, M.L., Escribano, L., Bárez, A., Moro, M.J., Hernández, J., Aguilera, C., Cuello, R., García-Frade, J., López, R., Portero, J., Orfao, A.

“…Immunophenotyping has become an essential tool for diagnosis of hematological malignancies. By contrast, for diagnosis of Waldenstrom's macroglobulinemia (WM)…”
Get full text

PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma by Paiva, B, Azpilikueta, A, Puig, N, Ocio, E M, Sharma, R, Oyajobi, B O, Labiano, S, San-Segundo, L, Rodriguez, A, Aires-Mejia, I, Rodriguez, I, Escalante, F, de Coca, A G, Barez, A, San Miguel, J F, Melero, I

Get full text

Multiparameter flow cytometry for the identification of the Waldenström’s clone in IgM-MGUS and Waldenström’s Macroglobulinemia: new criteria for differential diagnosis and risk stratification by Paiva, B, Montes, M C, García-Sanz, R, Ocio, E M, Alonso, J, de las Heras, N, Escalante, F, Cuello, R, de Coca, A G, Galende, J, Hernández, J, Sierra, M, Martin, A, Pardal, E, Bárez, A, Alonso, J, Suarez, L, González-López, T J, Perez, J J, Orfao, A, Vidríales, M-B, San Miguel, J F

“…Although multiparameter flow cytometry (MFC) has demonstrated clinical relevance in monoclonal gammopathy of undetermined significance (MGUS)/myeloma,…”
Get full text

Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients by García‐Sanz, R., González‐Fraile, M.I., Mateo, G., Hernández, J.M., López‐Berges, M.C., de las Heras, N., Fernández‐Calvo, J., Ortega, F., Portero, J.A., Bárez, A., Galende, J., Orfão, A., San Miguel, J.F.

“…Although multiple myeloma (MM) is predominantly a disease of the elderly, few studies have focused on the identification of prognostic factors in this group of…”
Get full text

Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma by González-Calle, V, Dávila, J, Escalante, F, de Coca, A G, Aguilera, C, López, R, Bárez, A, Alonso, J M, Hernández, R, Hernández, J M, de la Fuente, P, Puig, N, Ocio, E M, Gutiérrez, N C, García-Sanz, R, Mateos, M V

“…The diagnosis of smoldering multiple myeloma (SMM) includes patients with a heterogeneous risk of progression to active multiple myeloma (MM): some patients…”
Get full text

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma by Flores-Montero, J, Sanoja-Flores, L, Paiva, B, Puig, N, García-Sánchez, O, Böttcher, S, van der Velden, V H J, Pérez-Morán, J-J, Vidriales, M-B, García-Sanz, R, Jimenez, C, González, M, Martínez-López, J, Corral-Mateos, A, Grigore, G-E, Fluxá, R, Pontes, R, Caetano, J, Sedek, L, del Cañizo, M-C, Bladé, J, Lahuerta, J-J, Aguilar, C, Bárez, A, García-Mateo, A, Labrador, J, Leoz, P, Aguilera-Sanz, C, San-Miguel, J, Mateos, M-V, Durie, B, van Dongen, J J M, Orfao, A

“…Flow cytometry has become a highly valuable method to monitor minimal residual disease (MRD) and evaluate the depth of complete response (CR) in bone marrow…”
Get full text

Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications by García-Sanz, R, González, M, Orfão, A, Moro, M J, Hernández, J M, Borrego, D, Carnero, M, Casanova, F, Bárez, A, Jiménez, R, Portero, J A, San Miguel, J F

“…The aim of this study was to analyse the expression of NK-associated antigens in both peripheral blood and bone marrow lymphocytes from a large series of newly…”
Get more information

Functional expression of MDR-1 in acute myeloid leukemia : correlation with the clinical-biological, immunophenotypical, and prognostic disease characteristics by MARTINEZ, A, SAN MIGUEL, J. F, VALVERDE, B, BAREZ, A, MORO, M. J, GARCIA-MARCOS, M. A, PEREZ-SIMON, J. A, VIDRIALES, B, ORFAO, A

“…Up till now, clinical data on the possible prognostic influence of multidrug resistance (MDR) in hematological malignancies have been inconsistent, probably…”
Get full text

Analysis and clinical correlation of infiltrating cytotoxic T cells in Hodgkin Lymphoma tumor samples using flow cytometry by Alonso-Alvarez, Sara, Vidriales, Belen, Caballero, Maria Dolores, Davila, Julio, Caballero, Juan Carlos, Gonzalez-Calle, Veronica, Lopez-Godino, Oriana, Perez-Lopez, Estefania, Blanco, Oscar, Peñarrubia, Maria Jesús, Zato, Esther, Galende, J, Barez, A, Gonzalez, Marcos, García-Sanz, Ramon

Get full text

211 SPANISH REGISTRY OF ERYTHROPOIETIC STIMULATING AGENTS STUDY: THE LARGEST RETROSPECTIVE STUDY OF ESAS FOR THE TREATMENT OF ANEMIA IN LOWER RISK MDS PATIENTS by Campelo, M. Diez, Lorenzo, J.I, Benlloch, L, Lopez-Pavia, M, Such, E, Bernal, T, Luño, E, Davila, J, Ramos, F, Calabuig, M, Pomares, H, Gonzalez, B, Merchan, B, Barranco, E, Tello, R. Sancho, Callejas, M, Requena, M.J, Jimenez, M.J, Pedreño, M, Vicente, A.I, Medina, A, Campeny, A, Sansa, M. Cortes, Pedro, C, Falantes, J.F, Arilla, M.J, Barez, A, Garcia, R, Arcos, M.J, Gomez, V, Muñoz, C, Cervero, C, Casaño, J, de Paz, R, Amigo, L, Insunza, A, Muñoz, J.A, Cedena, M.T, Gomez, M, Font, P, del Campo, R, Lago, C. Fernandez, Hurtado, J.A. Gonzalez, Latorre, M.D. Linares, Casado, A. Mora, Vahi, M, Sanz, G.F, Cañizo, M.C

Get full text

Immunoparesis Recovery as Predictor Marker of Progression After Autologous Stem Cell Transplantation in Multiple Myeloma by González de la Calle, V, Sobejano, E, Dávila, J, Ocio, E, Puig, N, Gutiérrez, N, García-Sanz, R, García de Coca, A, Hernández, J.M, Hernández, R, Barez, A, Alonso, J.M, Aguilera, C, Escalante, F, Martin, G, López, R, de la Fuente, P, Labrador, J, Aguilar, C, Mateos, M.V

Get full text

Subcutaneous Bortezomib Plus Melphalan and Prednisone (VMP) in Non-Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) Patients: Spanish Experience by De Arriba, F, Vidal, S, Duran, S, Alvarez, M.A, Lopez San Roman, I, Dios, A, Rios, R, S. Gonzalez, M, Prieto, E, Garcia, R, Barez, A, Escalante, E, Clavero, C, Tejedor, A, Capote, F.J, Cabañas, V, Ballesteros, M, Couto, C, Zamudio, G, Mateos, M.V

Get full text

IMPACT OF DISEASE TREATMENT ON THE OUTCOME OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH COVID‐19: A MULTICENTER STUDY ON BEHALF OF GELLC by Muntañola, A., Mirás, F., Hernández‐Rivas, J. A., Baile, M., Osorio, S., Terol, Ma J., Gimeno, E., Alonso, R., Baltasar, P., López‐García, A., Labrador, J., López‐Jiménez, J., Hernández‐Rodríguez, I., Alfayate, A., Oliveira, A. C, Gómez‐Roncero, Ma I., Vidal, Ma J., Bárez, A., López‐Rubio, M., Riaza, R., Correa, J., Hernández‐Sánchez, E., Romero, P., Yáñez, L., Andreu, R., Santiago, R., Zabalza, A., Torres, A., Seri, C., Ramírez‐Payer, A., García‐Malo, Ma D., García‐Pintos, M., Mateos Mazón, J. J., Rodríguez‐Fernández, A., Ma Vale, A., Ríos, E., Loscertales, J., Do Nascimiento, J., Pérez‐Fernández, I., José Lis, Ma, Pérez, S., Ruiz, Ma E., Villalón, L., Velasquez, C. A., Campoy, F., Muiña, B., Soler, J. A., Sánchez, Ma J., Cuesta, A., Pimentel, A., Sánchez‐Ramírez, M., Ruiz‐Camps, I., Villacampa, G., Bosch, F., Abrisqueta, P.

Get full text

PS1398 RECOVERY OF POLICLONAL IMMUNOGLOBULINS AS A PREDICTOR FACTOR OF INCREASED PROGRESSION‐FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA INELIGIBLE FOR ASCT by Dávila, J., González‐Calle, V., Puig, N., Bárez, A., Escalante, F., López, R., Alonso, J.M., Aguilar, C., García‐Mateo, A., Contreras, T., Labrador, J., Aguilera, C., Coca, A. García, Hernández, R., Mateos, M.V., Ocio, E.M.

“…Background: Immunoparesis is the suppression of polyclonal immunoglobulins and is present in about 85% of patients diagnosed of multiple myeloma (MM). Our…”
Get full text

Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma by García-Sanz, R, Hernández, JM, Sureda, A, García-Laraña, J, Prósper, F, Alegre, A, Bárez, A, Mateos, MV, San Miguel, JF

“…Melphalan & Prednisone (MP) is considered as the standard therapy for Multiple Myeloma (MM) patients not eligible for high‐dose therapy. Here, we report the…”
Get full text

Geographical discrimination of honeys by using mineral composition and common chemical quality parameters by González Paramás, Ana M, Gómez Bárez, J Alfonso, Garcia-Villanova, Rafael J, Rivas Palá, Teresa, Ardanuy Albajar, Ramón, Sánchez Sánchez, José

“…Sixty honey samples from six different production zones of the provinces of Salamanca, Zamora and Cáceres (western Spain) were analysed for 13 common legal…”
Get full text

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA by Bladé, Joan, Rosiñol, Laura, Sureda, Ana, Ribera, Josep M., Díaz-Mediavilla, Joaquín, García-Laraña, José, Mateos, M. Victoria, Palomera, Luis, Fernández-Calvo, Javier, Martí, Josep M., Giraldo, Pilar, Carbonell, Félix, Callís, Manel, Trujillo, Jesús, Gardella, Santiago, Moro, M. Jesús, Barez, Abelardo, Soler, Alfons, Font, Llorenç, Fontanillas, Montserrat, Miguel, Jesús San

“…The aim of the present randomized trial was to compare high-dose therapy (HDT) with continued conventional chemotherapy in patients with multiple myeloma (MM)…”
Get full text

Relationship of transfusion and infectious complications after gastric carcinoma operations by Pinto, V, Baldonedo, R, Nicolas, C, Barez, A, Perez, A, Aza, J

“…To determine the effect of transfusion on the incidence of postoperative infection, a retrospective cohort study of 196 patients who underwent surgery for…”
Get more information

Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project by GIRALDO, Pilar, ALFONSO, Pilar, ATUTXA, Koldo, FERNANDEZ-GALAN, María A, BAREZ, Abelardo, FRANCO, Rafael, ALONSO, Dora, MARTIN, Alejandro, LATRE, Paz, POCOVI, Miguel

“…There are few published data from real-world clinical experience with miglustat (Zavesca), an oral inhibitor of glucosylceramide synthase, in type 1 Gaucher…”
Get full text

Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance by Almeida, J, Orfao, A, Mateo, G, Ocqueteau, M, García-Sanz, R, Moro, M J, Hernandez, J, Ortega, F, Borrego, D, Barez, A, Mejido, M, San Miguel, J F

“…In the present paper we review the immunophenotypic characteristics of plasma cells (PC) and the PC DNA contents from multiple myeloma (MM) and monoclonal…”
Get more information